StreetInsider.com News Articles

Form 8-K GYRE THERAPEUTICS, INC. For: Jul 10

Thu, 16 Jul 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260716/26780150.html

Form 8-K GYRE THERAPEUTICS, INC. For: Jul 10

Thu, 16 Jul 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260716/26780150.html

Gyre Therapeutics adds three directors to its board

Thu, 16 Jul 2026 16:05:13 -0400

Gyre Therapeutics, Inc. (Nasdaq: GYRE) announced the appointment of three new members to its board of directors, effective August 1, 2026, according to a press release.

The new directors are Yue Xiong, Ph.D., the company's Chief Scientific Officer; Maxwell Kirkby; and Claire Weston, Ph.D.

Dr. Xiong will serve as a Class I director with a term expiring at the 2028 annual stockholder meeting. He has served as Gyre's Chief Scientific Officer since May 2026 and previously held the same role at Cullgen, Inc. before its merger with Gyre. He is a former professor at the University of North Carolina at Chapel Hill

Gyre Therapeutics Appoints Three New Members to its Board of Directors

Thu, 16 Jul 2026 16:05:00 -0400

SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that its Board of Directors has appointed three new members, effective August 1, 2026: Yue Xiong, Ph.D., the Company's Chief Scientific Officer; Maxwell (“Max”) Kirkby; and Claire Weston, Ph.D. With these appointments, the Board expands its scientific, clinical development, and cross-border biopharmaceutical operating expertise as Gyre advances its broad pipeline of products targeting numerous therapeutic areas including fibrosis, cancer, inflammation and pain.

Dr.

Gyre Therapeutics Appoints Three New Members to its Board of Directors

Thu, 16 Jul 2026 16:05:00 -0400

Dr.

Form 8-K/A GYRE THERAPEUTICS, INC. For: May 04

Wed, 15 Jul 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260715/26774920.html

Form 8-K/A GYRE THERAPEUTICS, INC. For: May 04

Wed, 15 Jul 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260715/26774920.html

Gyre Therapeutics (GYRE) files for 31.03M share offering by selling stockholders

Mon, 13 Jul 2026 17:13:21 -0400

Gyre Therapeutics (NASDAQ: GYRE) has filed for up to 31,302,863 share offering by selling stockholders.

Gyre Therapeutics (GYRE) files for 31.03M share offering by selling stockholders

Mon, 13 Jul 2026 17:13:21 -0400

Gyre Therapeutics (NASDAQ: GYRE) has filed for up to 31,302,863 share offering by selling stockholders.

Form S-3/A GYRE THERAPEUTICS, INC.

Mon, 13 Jul 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260713/26763122.html

Form S-3/A GYRE THERAPEUTICS, INC.

Mon, 13 Jul 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260713/26763122.html

Form 4 GYRE THERAPEUTICS, INC. For: Jun 10 Filed by: Nussbaum Rodney L